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Abstract
The multifactorial likelihood analysis method has demonstrated utility for quantita-
tive assessment of variant pathogenicity for multiple cancer syndrome genes.
Independent data types currently incorporated in the model for assessing BRCA1 and
BRCA2 variants include clinically calibrated prior probability of pathogenicity based
on variant location and bioinformatic prediction of variant effect, co‐segregation,
family cancer history profile, co‐occurrence with a pathogenic variant in the same
gene, breast tumor pathology, and case‐control information. Research and clinical
data for multifactorial likelihood analysis were collated for 1,395 BRCA1/2
predominantly intronic and missense variants, enabling classification based on
posterior probability of pathogenicity for 734 variants: 447 variants were classified
as (likely) benign, and 94 as (likely) pathogenic; and 248 classifications were new or
considerably altered relative to ClinVar submissions. Classifications were compared
with information not yet included in the likelihood model, and evidence strengths
aligned to those recommended for ACMG/AMP classification codes. Altered mRNA
splicing or function relative to known nonpathogenic variant controls were
moderately to strongly predictive of variant pathogenicity. Variant absence in
population datasets provided supporting evidence for variant pathogenicity. These
findings have direct relevance for BRCA1 and BRCA2 variant evaluation, and justify
the need for gene‐specific calibration of evidence types used for variant classification.
K E YWORD S
BRCA1, BRCA2, classification, clinical, multifactorial, quantitative, uncertain significance, variant
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1 | INTRODUCTION
BRCA1 and BRCA2 variants resulting in abrogated function of the
encoded proteins confer a high risk of breast and ovarian cancer
(Antoniou et al., 2003; Kuchenbaecker et al., 2017), and have been
reported to increase risk of several other cancer types (Breast
Cancer Linkage C, 1999; Ford, Easton, Bishop, Narod, & Goldgar,
1994; Moran et al., 2012; Thompson, Easton, & Breast Cancer
Linkage C, 2002). The cancer types commonly considered important
for risk assessment are breast (female and male), ovarian, prostate,
and pancreatic cancer, all of which are included in the BOADICEA
model predicting risk of cancer for BRCA1 and BRCA2 pathogenic
variant carriers (Antoniou et al., 2008). Identification of a pathogenic
BRCA1 or BRCA2 variant is important clinical information that directs
medical management of an individual, including strategies aimed at
prevention (risk‐reducing surgery or medication), early detection
(presymptomatic screening), and more recently personalized treat-
ment with PARP‐inhibitors (Pilie, Tang, Mills, & Yap, 2019). Further,
cascade testing of close relatives of a pathogenic variant carrier is an
efficient and cost‐effective way to reduce the burden of cancer in
individuals at high risk of developing cancer (Tuffaha et al., 2018).
However, BRCA1 and BRCA2 variants of uncertain clinical signifi-
cance (VUS) identified by diagnostic testing continue to pose a
challenge for management of patients and their relatives.
ENIGMA (Evidence‐based Network for the Interpretation of
Germline Mutant Alleles) is an international research consortium
focused on developing and applying methods to determine the
clinical significance in breast‐ovarian cancer predisposition genes
(Spurdle et al., 2012). ENIGMA has developed variant classification
criteria that utilize both quantitative (statistical) and qualitative
(rules‐based) methods to assess the clinical significance of variants in
BRCA1 and BRCA2 (http://enigmaconsortium.org/). Quantitative
classifications of variants by ENIGMA are derived from the multi-
factorial likelihood model (Goldgar et al., 2004; Goldgar et al., 2008)
that combines multiple lines of clinical data in a Bayesian framework,
with the assumption that each feature is an independent predictor of
variant pathogenicity. The BRCA1/2 model components include
likelihood ratios (LRs) for pathogenicity estimated from clinical data,
such as co‐segregation with disease, co‐occurrence with a pathogenic
variant in the same gene, reported family history, breast tumor
pathology, and more recently, case‐control data (de la Hoya et al.,
2016; Easton et al., 2007; Goldgar et al., 2008; Spurdle et al., 2014;
Thompson, Easton, & Goldgar, 2003). This information is combined
with a prior probability of pathogenicity based on bioinformatic
predictions of variant effect on protein sequence or messenger RNA
(mRNA) splicing (Tavtigian, Byrnes, Goldgar, & Thomas, 2008; Vallee
et al., 2016), probabilities that have been calibrated against clinical
information, to produce a quantitative classification applicable across
many variant types. It should be noted that the reference sets used to
derive estimates of these LRs and prior probabilities were selected
such that the model is designed to assess if a variant demonstrates
the clinical features observed for a classical “high risk” variant. To
date there are 297 entries on the BRCA1/2 database displaying
variants classified by this method (http://hci‐exlovd.hci.utah.edu/
home.php), and for which there has been publication of the
breakdown of LRs for each component.
The American College of Medical Genetics and Genomics
(ACMG) and Association for Molecular Pathology (AMP) developed
a formal framework for using qualitative criteria for variant
classification, in an attempt to standardize the application of such
evidence (Richards et al., 2015). These guidelines are intended to be
generic, and thus some evidence codes will not be relevant for
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variant curation for a specific gene. The ClinGen consortium (Rehm
et al., 2015; https://www.clinicalgenome.org/) has engaged with
expert groups to develop adaptations of the guidelines to specify
which rule codes and strengths are appropriate for a specific gene‐
disease relationship, and to provide guidance on the phenotypic
features that are most predictive of variant pathogenicity (Rivera‐
Munoz et al., 2018). To date, adaptations of the ACMG/AMP criteria
have been completed for two hereditary cancer genes: PTEN (Mester
et al., 2018) and CDH1 (Lee et al., 2018), whereas other gene‐
adaptations are in development. In addition, ClinGen has approved
two additional expert panels arising from pre‐existing international
research consortia, for the curation of variants in the mismatch
repair genes (InSiGHT, International Society for Gastrointestinal
Hereditary Tumours; https://www.insight‐group.org), and in BRCA1
and BRCA2 (ENIGMA; http://enigmaconsortium.org/). The classifica-
tion criteria used by these groups pre‐dated the development of
ACMG/AMP adaptations, and use quantitative methods (as noted
above) and qualitative criteria not yet cross‐mapped to ACMG/AMP
codes. The ClinGen Sequence Variant Interpretation Working Group
recently demonstrated that the ACMG/AMP criteria were broadly
compatible with Bayesian statistical reasoning, and estimated LR
ranges appropriate for code strengths (Tavtigian et al., 2018).
Reference data is essential to calibrate the appropriate gene‐
specific strength of different curation evidence types, and also to
assess if evidence strength is the same for variants with different
molecular effects. In relation to BRCA1 and BRCA2, most variants
established to be pathogenic are premature truncation variants
(including nonsense or frameshift), and thus comprise the majority of
variants in reference sets used to calibrate predictors of BRCA1/2
variant pathogenicity. We have collated data from >40 clinical sites
within ENIGMA and from other international clinical collaborators to
conduct the largest application of the multifactorial likelihood model
to missense and intronic variants in BRCA1 and BRCA2, providing
quantitative variant classifications, and also scores for the compo-
nent data types so as to demonstrate their relative contributions to
the final posterior probability. We have also demonstrated the value
of this dataset as a resource for calibrating qualitative information
for application to BRCA1/2 variant classification, and deriving BRCA1/
2‐appropriate rule strengths for several ACMG/AMP evidence codes.
2 | METHODS
2.1 | Variant selection for data collection
At the time of joining ENIGMA, members were asked to submit all
variants in BRCA1 and BRCA2 that they considered to be of
uncertain clinical significance, together with the number of families
carrying each variant. We followed the rationale that high‐risk
variants will not occur commonly in the general population, as
indicated by frequency measured in outbred reference datasets
representative of subpopulations. Variants were thus classified as
Class 1 Not Pathogenic if they were identified to occur at minor
allele frequency >0.01 in one or more of the following datasets:
South Asian, Latino, African, East Asian, Non‐Finnish European
subpopulations from the Exome Aggregation Consortium (ExAC)
dataset (after excluding cancer‐related information from The
Cancer Genome Atlas (TCGA; http://exac.broadinstitute.org); Eur-
opean, African, Admixed American, East Asian, or South Asian
sample sets from the 1000 Genomes Project (http://www.
1000genomes.org). This exercise provided a baseline variant list
for subsequent ENIGMA studies. For the analysis presented in this
study, a subset of variants were prioritized for collection of
segregation and breast tumor pathology data, based on number of
observations/families in the initial ENIGMA variant list and/or
bioinformatic score indicative of pathogenicity. Information for co‐
segregation analysis was provided in the form of a deidentified
pedigree for families with known carrier status in more than one
individual. Pedigree details included sex, cancer status, and age at
cancer diagnosis, or age at interview if unaffected. Unaffected
individuals known to have undergone prophylactic surgery (mas-
tectomy or oophorectomy) were censored at age of earliest surgery.
Breast tumor pathology information collected for known variant
carriers included hormone receptor status (estrogen receptor [ER],
progesterone receptor [PR], human epidermal growth factor
receptor 2 [HER2]), and/or tumor grade. In addition, clinical queries
to the Spurdle laboratory led to the collation of additional
segregation and pathology information of potential value for
multifactorial likelihood analysis of individual variants. Further,
genotype data generated as part of the iCOGS project was available
via collaboration with the Breast Cancer Association Consortium
(BCAC) for a subset of variants, from up to 41,141 breast cancer
cases and 38,694 controls of European ancestry, and 6,185 breast
cancer cases and 6,614 controls of Asian ancestry (Michailidou
et al., 2013). Variants included in the iCOGS project were
prioritized for genotyping using the same approach as for the
baseline ENIGMA variant list, with additional variants selected due
to laboratory/bioinformatic evidence for effect on mRNA splicing.
For each variant, a positive control DNA from a variant carrier was
submitted for genotyping to facilitate calling of these rare variants.
Lastly, we included a subset of variants for which multifactorial
likelihood analysis results had previously been published, but the
final classification reported was not “Class 5 Pathogenic” or “Class 1
Not Pathogenic”, and/or LRs were not all visible in the original
publication (Easton et al., 2007; Farrugia et al., 2008; Lindor et al.,
2012). Information from all these sources was collated for a total of
3,295 variants. This amalgamated list of variants was then
circulated by email to ENIGMA consortium members to invite them
to provide additional segregation or pathology information for
inclusion in the analysis. Where relevant, additional nonoverlapping
pathology or segregation information was sourced directly from
publications for inclusion in the analysis. Overall, there were 1,008
informative pathology data points and 895 informative families for
segregation analysis from ENIGMA collaborators, clinical enquiries,
and nonoverlapping publications (see below for further explanation
about LR assignment). After combining all information, at least one
data point was available for 1,395 variants.
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Variant descriptions are in accordance to HGVS recommenda-
tions. Nucleotide numbering corresponds to reference transcripts
NM_007294.3 (BRCA1) and NM_000059.3 (BRCA2). Legacy descrip-
tion is also provided to assist comparison with historical records in
the literature; the nucleotide numbering is from nucleotide one of the
full gene sequence (Genbank: U14680.1/BRCA1; U43746/BRCA2) not
the ATG initiator codon, and BRCA1 exon boundaries are from
GenBank U14680.1 with exon four missing due to a correction made
after the initial description of the gene.
2.2 | Multifactorial likelihood analysis
A Bayesian model was used to combine evidence as previously
described (Goldgar et al., 2008). In brief, the prior probability of
pathogenicity was assigned based on a combination of Align‐GVGD
score and MaxEntScan splicing predictions, overlaid with expert
knowledge incorporating prediction of variant effect on critical
functional protein domains (Tavtigian et al., 2008; Vallee et al., 2016).
Applicable prior probability of pathogenicity predictions for single
nucleotide variants in BRCA1 and BRCA2 are available from the HCI
Database of Prior Probabilities of Pathogenicity for Single Nucleotide
Substitutions (http://priors.hci.utah.edu/PRIORS/). Align‐GVGD does
not score in‐frame insertions and deletions, therefore to estimate
prior probabilities for in‐frame deletion variants studied, we took the
highest Align‐GVGD prior of the deleted bases. There were no in‐
frame exonic insertions included in this study. The higher of the two
priors (missense vs. splicing) was assigned for analysis. Co‐segrega-
tion analysis was performed as described by Thompson et al. (2003)
for each family with more than one individual genotyped for the
variant. Hazard ratio estimates were taken from Antoniou et al.
(2003) for <30, 30–39, 40–49, 50–59, 60–69, 70–79, and 80+ age
brackets. For individuals affected with ovarian cancer at 20–29
years, penetrance for ovarian cancer at age 30–39 was applied due to
a lack of information in the younger penetrance class (Antoniou et al.,
2003). If no age at last update was provided by the submitting center
for unaffected individuals, test date was used to infer current age.
Breast tumor pathology LRs were assigned based on the estimates in
Spurdle et al. (2014), and considered age at diagnosis. When multiple
tumors were present in one individual, the first diagnosed tumor with
information available was taken, and only a single LR was assigned
according to the extent of information available (out of the variables
tumor grade, ER, PR, and HER2), following previous recommenda-
tions (Spurdle et al., 2014). Likelihood ratios for co‐occurrence with a
pathogenic variant (in trans), and reported family history analysis,
were drawn from a previous publication (Easton et al., 2007).
Case‐control data from the iCOGS project were used to estimate LRs
following methods described previously (de la Hoya et al., 2016).
Table S1 summarizes the LRs assigned for each component for
each variant with at least one data point. Prior probabilities and LRs
were combined to calculate posterior probabilities using Bayes rule:
(Prior Probability x Combined LR)/(Prior Probability x [Combined
LR + {1 − Prior Probability}]). Where multiple data points were
available for a single data type, for example, segregation, LRs were
combined multiplicatively. Using variant BRCA1 c.131G>T as an
example: Prior Probability is 0.81; Combined LR is 6,440.7 (based on
LR Segregation (156.17) x LR Pathology (41.24) x LR Co‐occurrence
(a) x LR Family History (a) x LR Case‐Control (a)). Posterior prob-
ability is 0.99996, calculated as (0.81 × 6440.7)/(0.81 × [6440.7 + {1‐
0.81}]). Breakdown of clinical data type contributed, and the data
sources (submitter, publication source), are shown in Table S2.
It has previously been proposed that a combined LR between 0.5
and 2, in particular if derived from a limited number of data points,
provides insufficient observational data to perform a valid integrated
analysis (Vallee et al., 2016). This is in accord with the idea that
ACMG guidelines intrinsically include an indeterminate zone,
between supporting benign and supporting pathogenic, for variants
with insufficient or conflicting evidence for pathogenicity. Following
this rationale, posterior probabilities of pathogenicity were not
calculated for any variant with a combined LR between 0.5 and 2.
Posterior probability of pathogenicity was calculated for a total of
734 variants, and classification assigned based on previously
published cut‐offs proposed for the International Agency for
Research into Cancer (IARC) five tier classification scheme (Plon
et al., 2008), with some modification of terms used to describe tiers
(Spurdle et al., 2019), namely: Class 5 Pathogenic, >0.99; Class 4
Likely Pathogenic, 0.95–0.99; Class 3 Uncertain, 0.05–0.949; Class 2
Likely Benign, 0.001–0.049; and Class 1 Benign, <0.001. The variant
classifications, with breakdown of LR components and sources, have
been submitted to the following databases for public display:
<http://hci‐exlovd.hci.utah.edu/home.php?select_db=BRCA1>
<http://hci‐exlovd.hci.utah.edu/home.php?select_db=BRCA2>
2.3 | Datasets providing information for
comparison and calibration of qualitative
classification criteria
2.3.1 | ClinVar assertions
Variant pathogenicity assertions from ClinVar were taken from the
November 2018 XML file. Summary annotation and individual
submitter annotations are recorded in Table S1 (columns ClinVar
Class Summary, ClinVar Class Details by Submitter). A small number
of variants included had previously been reviewed by the ENIGMA
BRCA1/2 Expert Panel, but these have not been specifically
annotated as the primary purpose of the comparison with ClinVar
assertions was to identify discrepancies with classifications derived
from this updated multifactorial likelihood analysis.
2.3.2 | mRNA splicing assay data
Published mRNA splicing assays of BRCA1 and BRCA2 variants were
collated for a previous ENIGMA project (Walker et al., 2013), a
resource which has been updated over time. Details of transcripts
observed were recorded, and nomenclature errors for variant and
transcripts corrected as necessary. We matched these results against
the 1,395 variants included in this study (Table S1). Assays that
provided variant allele‐specific transcript results from patient‐derived
1564 | PARSONS ET AL.
mRNA were noted as being eligible for assessment according to the
ENIGMA classification guidelines, and effect on mRNA splicing was
coded as none, partial, or complete (column Coded Splicing Effect). All
other assay results (including additional assays of patient mRNA that
did not measure allele‐specific expression, and construct‐based
assays), were noted as to whether the variants were reported to
impact mRNA splicing profile or not (column Allele‐Specific Splicing
Result Summary). To simplify comparison with broad ACMG code
description, the relationship of aberrant transcript/s to protein effect
that is premature termination, disruption of clinically important
residues was not captured in the mRNA effect codes. Further, to limit
these LR measures to variant effect on mRNA splicing only, variants
classified as (Likely) Pathogenic that had high bioinformatic prediction
of effect on amino acid sequence were presumed to confer
pathogenicity via effect on protein function, and excluded from the
reference set for derivation of the mRNA splicing LRs. See Table S3 for
details of the variants included in mRNA splicing subanalysis, and code
assignments.
2.3.3 | Protein functional assay data
Seven relatively recent publications, providing results from different
mammalian‐based assays of protein function, were chosen for
comparison with classifications arising from multifactorial analysis.
Five publications were from ENIGMA members and incorporate
known pathogenic and known benign missense BRCA1 or BRCA2
variants as controls, permitting estimation of sensitivity, and
specificity of missense variant pathogenicity: (a) region‐limited
construct‐based transcriptional activation assays of missense var-
iants located across the BRCA1 Coiled Coil, BRCT1, Linker, and
BRCT2 domains (Fernandes et al., 2019); (b) full‐length complemen-
tary DNA (cDNA) construct‐based homologous recombination DNA
repair assays of missense variants in the BRCA2 C‐terminal DNA
binding domain (Hart et al., 2019); (c) a mouse embryonic stem cell‐
based assay of BRCA1 variants assessing the ability of full‐length
human BRCA1 cDNA to complement reduced cell proliferation
following deletion of a conditional mouse Brca1 allele, and cisplatin
sensitivity (Bouwman et al., 2013); (d) a mouse embryonic stem cell‐
based assay of BRCA2 variants assessing the ability of full‐length
genomic human BRCA2 to complement loss of cell viability following
deletion of a conditional mouse Brca2 allele, and follow‐on homo-
logous recombination assays of BRCA2‐expressing cells that are able
to complement cell lethality (Mesman et al., 2019); and (e) analysis of
homologous recombination for BRCA1 BRCT missense variants
expressed in mammalian cells as BRCT1–BRCT2 clones into pcDNA3
(modified)‐full‐length Brca1, followed by measures of human BRCA1
BRCT1–BRCA2 domain solubility (assayed in bacterial cells), and
phosphopeptide‐binding properties of the purified BRCT domain
variants in vitro (Petitalot et al., 2019). These selected studies were
the most recent publications arising from these research groups, and
incorporated research results from any prior publications from that
group. Two additional publications were selected as they provide
results from high‐throughput multiplex assays. The first was a
multiplex reporter assay characterizing the effects of 1,056 amino
acid substitutions in the first 192 residues of BRCA1 on homology‐
directed repair of double strand breaks (Starita et al., 2018). The
second was a high‐throughput saturation genome editing haploid cell
survival assay, measuring functional effect for single nucleotide
variants in 13 BRCA1 exons covering key functional domains (Findlay
et al., 2018): targeted genomic DNA sequencing and RNA sequencing
were used to quantify variant abundance and infer effect on BRCA1
function overall (DNA sequencing), and via effect on mRNA
production (RNA sequencing); function scores for different exons
were normalized by matching median scores for synonymous and
nonsense variants to global medians for these variant types. The
assay design for five of the seven studies permitted assay of effect on
protein only, and not mRNA levels or splicing. We thus excluded
“missense” variants that were known to alter mRNA levels or splicing,
or were located in the splicing motifs at the start/end of exons, such
that comparisons with results from functional studies should all be
limited to measures of variant effect on protein only. Effect on
function as assigned by the original publication was recoded into one
of three tiers (complete, partial, or no functional impact). A total of
77 unique variants assayed by at least one study were available for
comparison with multifactorial likelihood classifications. See Table S4
for details of the variants and functional code assignments. For
Mesman et al. (2019), results from complementation and homologous
recombination assay combined were used to assign final functional
effect as per recommendations from those authors. For Petitalot
et al. (2019), functional classification was based on a combination of
homologous recombination, BRCT solubility, and phosphopeptide
binding (from their own study and also reports in the literature), as
detailed in Table 1b of the publication (Petitalot et al., 2019).
2.3.4 | Reference population frequency data
Population frequency data were downloaded from the Genome
Aggregation Database (gnomAD non‐cancer v2.1 dataset; gnomad
.broadinstitute.org). Three large in‐frame deletion variants classified as
Pathogenic were excluded from the population frequency LR estima-
tion analysis, as frequencies are not provided by gnomAD for variants
of this type. No large deletion variants were classified as (Likely)
Benign. As an exercise to compare the validity of gnomAD as a
“control” reference dataset, we also compared the frequency of 17
variants detected at allele frequency <1% in European ancestry breast
cancer‐free controls (n = 38,694) genotyped as part of iCOGS, to
frequencies for the same variants observed in (a) non‐Finnish
Europeans from gnomAD (maximum n = 59,073, from genome and
exome data combined), and (b) European aged (>70 year old) cancer‐
free control from the FLOSSIES dataset (n = 7,325; https://whi.color.
com/). Our comparisons of variant frequency in gnomAD to those of
“true” controls of European ancestry (Table S5) indicated that variants
were more likely to be absent from the smaller FLOSSIES dataset (only
6/17 variants were observed), whereas the frequency category based
on the gnomAD non‐Finnish Europeans was the same as that for
iCOGS European ancestry controls for all 17 variants. The FLOSSIES
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African dataset provides allele frequencies based on 2,559 individuals
(5,118 alleles), which is considerably smaller than the gnomAD African
dataset. For this reason we opted to use only gnomAD outbred (non‐
founder) sample sets (non‐Finnish European [15,316–118,174],
African [8,664–23,620], Latino [22,398–35,108], South Asian
[21,600–30,526], East Asian [14,012–19,252]) to determine the
highest minor allele frequency observed based on exome and genome
data combined. Variants observed only once across all five outbred
sample sets were annotated as such for frequency LR estimation
(Table S1). Variants absent from all five outbred sample sets, but
present once in Finnish or Ashkenazi Jewish sample sets were
excluded from the frequency LR estimation (noted as “NA” in column
“Frequency Category Assigned for LR derivation” in Table S1).
Designation of LRs to ACMG/AMP rule code strengths were
based on LR ranges recently proposed as consistent with ACMG/
AMP qualitative rule strengths for future classification in a Bayesian
framework (Tavtigian et al., 2018). Namely: supporting evidence for
pathogenicity, LR 2.08–4.3; moderate evidence for pathogenicity, LR
4.3–18.7; and strong evidence for pathogenicity; LR 18.7–350. LRs
ranges for Benign code strengths were calculated as the inverse of
the ranges proposed for Pathogenic code strengths.
3 | RESULTS AND DISCUSSION
An IARC class informative for clinical management (Class 1 Benign,
Class 2 Likely Benign, Class 4 Likely Pathogenic, or Class 5 Pathogenic)
was reached for 541/734 (74%) of the 734 variants considered to have
sufficient information to inform calculation of a posterior probability of
pathogenicity (Table S1). The remaining 193/734 variants fell within the
wide range of 0.05–0.95 considered inconclusive of variant pathogeni-
city (Class 3 Uncertain). Overall, only 54 of the 541 variants with
posterior probability assigned have previously been assessed using the
multifactorial likelihood approach, and in some instances the clinical
evidence included previously did not pass thresholds that have since
been set for combined LR (between 0.5 and 2) considered informative
for quantitative analysis (see Methods). Of the 541 variants falling
outside of Class 3 Uncertain, 67 (9% of the 734 assessed) had a
posterior probability of pathogenicity > 0.99 (Class 5 Pathogenic), and
27 (4%) had a posterior probability of pathogenicity > 0.95 (Class 4
Likely Pathogenic), classifications which directly influence management
of variant carriers and their relatives (Table 1), with 447 (61%) classified
as (Likely) Benign. These findings are consistent with the knowledge
that the majority of missense and intronic variants in these genes will, a
priori, not be associated with a high risk of cancer as they fall outside of
or are unlikely to impact BRCA1 or BRCA2 protein functional domains.
Further, we draw attention in particular to two variants (BRCA2
c.516+1G>T and BRCA2 c.7007+1G>C) demonstrating differences
between multifactorial likelihood‐based analysis and the current
iteration of ENIGMA “rules‐based” qualitative assessment based on
mRNA splicing assay data from patient material (Houdayer et al.,
2012; Whiley et al., 2011). The splicing assay data, albeit not allele‐
specific, indicate that both variants impact splicing profile. According
to ENIGMA qualitative classification criteria, the BRCA2 c.516+1G>T
(intron 6) and BRCA2 c.7007+1G>C (intron 13) variants would be
classified as Class 4 Likely Pathogenic based on their location in a
donor dinucleotide ‐ in the absence of conflicting information.
Despite the high prior probability of 0.97 based on bioinformatic
prediction, the clinical information included in this study provided
sufficient evidence against pathogenicity that the posterior prob-
ability fell below 0.95 (0.81 for BRCA2 c.516+1G>T, 0.78 for BRCA2
c.7007+1G>C). For BRCA2 c.7007+1G>C, the variant was identified
in the breast cancer affected proband but not in the one affected
relative tested. For BRCA2 c.516+1G>T, only two of four affected
relatives tested were carriers. Although both variants have been
submitted to ClinVar as pathogenic by multiple submitters; summary
evidence was provided for only one assertion for BRCA2
c.7007+1G>C, and refers to variant location and splicing assay data
with no additional clinical details. Interestingly, unpublished results
from mouse embryonic stem cell assays M.P.G. Vreeswijk (personal
communication, 22 January 2019) indicate that BRCA2 c.7007+1G>C
has a severe impact on function as measured by failure to
complement the lethal cell phenotype, whereas BRCA2 c.516+1G>T
does not have a severe impact on function (complementation; 56%
HDR capacity, within the range for variants previously placed in Class
1/2 by multifactorial likelihood analysis). The combined observations
for these two variants raise the complex issue of what constitutes
sufficient conflicting information when assigning a qualitative
classification, or perhaps even in the context of LRs included in a
quantitative classification calculation. The current classification in
ClinVar as Likely Pathogenic would appear to be consistent with
ACMG‐derived classifications used in clinical practice, but we
strongly recommend prioritized collection of additional clinical,
splicing and functional data to provide more extensive information
in support of assertions for these two variants.
Overall, comparison of classes assigned by multifactorial like-
lihood analyses and pathogenicity assertions in ClinVar revealed that
of the 94 variants classified as (Likely) Pathogenic by multifactorial
likelihood analysis conducted in this study, 80 have at least one
assertion as (Likely) Pathogenic, seven are Uncertain, and seven are
currently not in ClinVar; that is none were submitted as (Likely)
Benign. Of the 447 variants classified as (Likely) Benign using
multifactorial analysis, 212 have at least one assertion as (Likely)
Benign, 234 were either uncertain in or absent from ClinVar, and the
remaining variant BRCA1 c.5453A>G p.(Asp1818Gly) is actually a
spliceogenic variant with four assertions as (Likely) Pathogenic. The
explanation for this discrepancy is detailed below. Altogether, these
results can now be used to contribute to ENIGMA expert panel
classification of 541 variants, 248 of which are new or considerably
altered compared to current submissions to ClinVar.
3.1 | Correlation of multifactorial likelihood
classifications with splicing assay data
Current ENIGMA BRCA1/2 classification criteria for spliceogenic
variants, consistent with those of the InSiGHT Consortium developed
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for classification of mismatch repair gene variants (Thompson et al.,
2014), present stringent recommendations for use of mRNA splicing
data for variant interpretation (https://enigmaconsortium.org).
Namely, a variant is only considered pathogenic on the basis on
mRNA splicing data if there is no predicted functional transcript
produced from the variant allele, as determined by assays of patient‐
derived mRNA that have assessed allele‐specific expression of
alternate transcripts. This stipulation is not specified for ACMG/
AMP classification codes using splicing data (PS3, well‐established in
vitro or in vivo functional studies supportive of a damaging effect on
the gene or gene product).
We undertook a comparison of multifactorial model classifica-
tions against published splicing assays results (including assays of
patient material and construct‐based assays) to calibrate use of
splicing assay data for use as weighted information for qualitative
classification, based on the LR ranges recently proposed as consistent
with ACMG/AMP qualitative rule strengths for future classification
in a Bayesian framework (Tavtigian et al., 2018). Of the variants
falling outside of Class 3 Uncertain in this analysis, 99 had mRNA
splicing data available, 25 of which had been assessed using allele‐
specific assays of mRNA from patient tissue. By comparing splicing
effect to classifications derived from this study, we estimated a LR
towards pathogenicity based on effect on mRNA splicing (Table 2;
Table S3 for additional details). The very limited number of allele‐
specific assays did not allow for robust estimates of LRs, with the
confidence intervals for LRs estimated for both partial and complete
effect on splicing including unity. Nevertheless, results support the
hypothesis that partial effect on splicing will not be as strongly
predictive of pathogenicity as is complete effect on splicing (LR 3.82
vs. LR 6.36 from this analysis). Including all assay results, no effect on
splicing provided strong evidence against pathogenicity (LR 0.02),
whereas any impact on splicing (without measurement of allele‐
specific effects, or consideration of in‐frame transcripts) provided
moderate evidence for pathogenicity (LR 12.24). Recognizing the
small sample sizes, and consequently large confidence limits, these
results nevertheless demonstrate the value of mRNA splicing assays
as a component in qualitative variant classification. We also highlight
the possibility that there is likely to be considerable bias in variants
selected for mRNA assays, with over‐representation of variants
at the highly conserved donor and acceptor dinucleotides, positions
that, when altered, are likely to impact splicing more severely than
spliceogenic variants located at other positions. We thus stress the
importance of incorporating allele‐specific expression assays into
variant evaluation processes wherever possible, and to revisit such
analysis with larger datasets in the future. We also recommend that
future larger‐scale comparisons to derive LRs for splicing assay data
should consider in greater detail the predicted impact of the aberrant
mRNA profiles on protein function, and in particular consider the
relevance of in‐frame isoforms that could be translated to result in
(partially) functional protein. Further, as both partial mRNA splicing
and in‐frame transcripts may be associated with reduced cancer
penetrance that is not inherently captured by the design of the
multifactorial model, family‐based and case‐control studies may beT
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necessary to tease out which such spliceogenic variants are indeed
risk‐associated, and if this level of risk is clinically actionable.
We then considered qualitative classification based on mRNA
splicing results for all variants with a multifactorial likelihood
calculation that is including Class 3 Uncertain variants (See Table S1,
columns Splicing Results/s and Allele‐Specific Assay). Following
ENIGMA BRCA1/2 qualitative classification criteria (http://
enigmaconsortium.org/), there were 15 variants that could be
interpreted as Pathogenic based on splicing, that is no predicted
functional transcript produced from the variant allele; of these,
multifactorial data classified five as (Likely) Pathogenic, five as
Uncertain, whereas four had insufficient data to perform a calculation.
BRCA1 c.5453A>G was the only variant with truly discordant
classification between splicing results (Class 5 Pathogenic) and
multifactorial data analysis (Class 2 Likely Benign); the multifactorial
classification was based on low prior probability of 0.03 for the
presumed missense substitution Asp1818Gly, one pathology data
point (LR 0.34), and relatively uninformative co‐occurrence (LR 1.12)
and family history (LR 0.91) data. This variant highlights a recognized
limitation of current bioinformatic predictions used in the multi-
factorial analysis; the variant alters splicing by modifying an exonic
splice enhancer (ESE; Rouleau et al., 2010). There are currently no
bioinformatic prediction tools with adequate sensitivity and specificity
to predict ESE loss or gain with any reliability, and this mechanism has
thus not yet been incorporated into bioinformatic prior probability
estimation. Although results from splicing assays can obviously add
value for such examples, the poor predictability of ESEs and effects of
variation on ESE function, hinders the prioritization of ESE‐altering
variants for splicing assays. We reiterate that the Class 2 Likely Benign
tier implicitly allows for a 5% error rate in classification, and resources
permitting, we would encourage additional data collection for all
variants falling in this tier. Moreover, future inclusion of a LR derived
for splicing impact as a component of the multifactorial likelihood
analysis, where such splicing information is available, would likely shift
the posterior probability for such variants into the range of Class 3
Uncertain and so prevent overt misclassification driven by
bioinformatic prediction deficiencies. At this point in time, we would
encourage additional clinical data collection for BRCA1 c.5453A>G to
confirm that the clinical phenotype is consistent with a Class 5
Pathogenic assertion based on splicing data only.
3.2 | Correlation of multifactorial likelihood
classifications with protein functional assay data
Functional assays are considered strong evidence for or against
pathogenicity using ACMG/AMP codes PS3 and BS3 (well‐estab-
lished in vitro or in vivo functional studies show (damaging/no
damaging) effect on gene or gene product). A range of different
assays have been used to assess effect of BRCA1 and BRCA2 variants
on protein function, some limited to measuring impact on function of
variants within a specific domain, and others measuring output
relevant to a variant located anywhere in the coding region. To
assess the strength of this evidence as a predictor of the clinical
significance of anticipated missense BRCA1 and BRCA2 variations, it
is important to consider several factors. Sensitivity and specificity of
assays should be determined using missense variants that have
previously been determined to be pathogenic or benign (Guidugli
et al., 2014; Millot et al., 2012); that is assay profiles for truncating
variants may not be appropriate to measure loss of function
displayed by pathogenic missense variants. To prevent circularity,
functional assay results should not have contributed to the
classification of these “control” missense variants, as may be the
situation for variants submitted to ClinVar as pathogenic. An
additional factor to consider, but not addressable at this point in
time, is that there are few BRCA1/2 variants robustly proven to be
associated with moderate risk of cancer. There is thus a paucity of
controls to calibrate assay results to detect moderate‐risk variants.
Moderate‐risk variants are intuitively expected to have less impact
on function than variants associated with a high cancer risk
comparable to that of the average truncating allele, and severity of
their impact on function may differ depending on the specific protein
effects measured (Lovelock et al., 2007).
TABLE 2 Splicing effect reported for variants classified as (Likely) Benign or (Likely) Pathogenic using multifactorial likelihood analysisa
Splicing effect
(Likely) benign (Likely) pathogenic
LR towards
pathogenicity
(95% confidence
interval)n % n %
Assays measuring allele‐specific expression
None 11 78.57 0 9.09b 0.12 (0.02–0.76)
Partial 2 14.29 6 54.55 3.82 (0.95–15.36)
Complete 1 7.14 5 45.45 6.36 (0.86–46.86)
Total 14 11
All splicing results
None 46 92.00 0 2.04b 0.02 (0.01–0.15)
Any impact 4 8.00 49 97.96 12.24 (4.78–31.35)
Total 50 49
aSee methods for overview of sources of mRNA splicing information, and categorization of splicing effect. Also see Table S3 for details of variants
included in comparison.
bPercentage is calculated assuming a single variant in this category, and thus provides a conservative estimate of the LR.
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For this reason, we compared our multifactorial analysis results
for missense variants classified outside of Class 3 Uncertain to
results from selected published functional assays (also see Methods).
Briefly, these included: (a) domain‐specific or generic assays
assessing variant effect on protein function, and calibrated against
missense variants previously classified as pathogenic or benign using
multifactorial likelihood analysis that is using bioinformatic and
clinical information (Bouwman et al., 2013; Fernandes et al., 2019;
Hart et al., 2019; Mesman et al., 2019; Petitalot et al., 2019); and (b)
multiplex reporter assays (Findlay et al., 2018; Starita et al., 2018)
reported to have reasonable to good sensitivity and specificity by
comparison to ClinVar classifications (including truncating, splicing,
and missense variants). There were 16 (Likely) Pathogenic and 61
(Likely) Benign variants with a protein functional assay result from at
least one study (Table 3; Table S4 for additional details). All 56
variants reported to have no functional impact were classified as
(Likely) Benign, as were the four of five variants demonstrating
partial function in at least one assay. The fifth variant BRCA1
c.5216A>T p.(Asp1739Val) was classified as Likely Pathogenic based
on posterior probability of 0.97. As outlined in Supp Table S4, this
missense substitution variant was reported to have complete loss of
function using transcription activation and cell survival assays, but
partial activity by Petitalot et al. (2019); the latter categorization was
based on the combination of somewhat decreased solubility,
decreased BACH1 binding (reported in yet another publication, Lee
et al. (2010)), and normal homologous recombination and localization
(Petitalot et al., 2019). Of the 16 variants reported to impact function
completely (and with no evidence otherwise by another of the
functional studies selected), 15 were classified by multifactorial
likelihood analysis as (Likely) Pathogenic, and the other as
(Likely) Benign. Of note, the latter variant BRCA2 c.8351G>A
p.(Arg2784Gln) did complement lethality in the mouse embryonic
stem cell assay (Mesman et al., 2019), but was coded as impacting
function based on homologous recombination assay results from the
same study (Mesman et al., 2019), and was reported to impact
homologous recombination in an independent study (Hart et al.,
2019). We note that for the two exceptions highlighted
(BRCA1 c.5216A>T, BRCA2 c.8351G>A), the results from survival
assays were concordant with the multifactorial likelihood classification.
Considering results overall, we estimated a LR towards pathogenicity
based on assays of protein function from at least one study (Table 3).
Acknowledging the caveat of small sample sizes, and at least one
observation (and thus liberal frequency estimates) assumed for cells
without counts, our results support use of functional assay data as
moderate or strong evidence in determining pathogenicity assertions for
missense variants. Specifically, complete impact on function with no
conflicting evidence is strongly predictive of missense variant pathogeni-
city (estimated LR 57.19, lower confidence bound 8.15). No impact on
protein function provides moderate evidence against missense variant
pathogenicity (LR 0.07 with upper bound 0.45, equating to an LR of 15.26
against pathogenicity). The results confirm the value of results from these
selected protein functional assays as a component in qualitative
classification of missense variants. They also stress the importance of
considering discordances across different assay methods as an approach
to select individual variants for further consideration as potential
moderate‐risk variants, variants that may not always be detectable as
risk‐associated using statistical models developed for high‐risk variants.
Further, as noted before, the BRCA1/2multifactorial model is designed to
capture clinical features of patients with the average high‐risk pathogenic
variant, and we cannot exclude the possibility that some variants
demonstrating impact on function (partial, or even complete for at least
one assay type) are moderate‐risk alleles. It will thus be important to
prioritize variants such as BRCA1 c.5216A>T p.(Asp1739Val) and BRCA2
c.8351G>A p.(Arg2784Gln), where some functional data conflict the
clinical information data (thereby arguably considered Uncertain accord-
ing to ACMG/AMP qualitative criteria) for further study as potential
moderate‐risk variants.
3.3 | Correlation of multifactorial likelihood
classifications with frequency in reference population
datasets
Variant frequency in disease‐free controls can be used to provide
evidence against pathogenicity, and indeed minor allele frequency
TABLE 3 Functional effect reported for missense substitution variants classified as (Likely) Benign or (Likely) Pathogenic using multifactorial
likelihood analysisa
Protein functional effect in at least 1
studyb
(Likely) benign (Likely) pathogenic
LR towards
pathogenicity
(95% confidence
interval)n % n %
None 56 91.80 0 6.25c 0.07 (0.01–0.45)
None/partial 3 4.92 0 N/A
Partial 1 1.64 0 N/A
Partial/complete 0 1 6.25 N/A
Complete 1 1.64 15 93.75 57.19 (8.15–401.14)
Total 61 16
aExcludes missense variants shown to be associated with altered mRNA splicing, or with reduced/absent mRNA expression from survival assays. See
Table S4 for details of variants included in comparison.
bFunctional impact codes assigned based on effect description as originally published. See Table S4 for more details.
cPercentage is calculated assuming a single variant in this category, and thus provides a conservative estimate of the LR.
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(MAF) > 1% in a nonfounder population is considered stand‐alone
evidence against pathogenicity for BRCA1/2 variants by the ENIGMA
consortium. An algorithm to define a “maximum credible population
allele frequency” (Whiffin et al., 2017) has been proposed as a
method to select MAF cut‐offs as evidence against pathogenicity, and
indeed was used as a basis to select relevant minor allele frequency
cut‐offs for the PTEN and CDH1 adaptations of ACMG/AMP rule
codes BA1 (stand‐alone) and BS1 (strong) evidence against patho-
genicity, described as “allele frequency is greater than expected for
the disorder.” The output of this algorithm can vary widely depending
on input assumptions for disease penetrance and prevalence of the
disorder, and is complicated for multicancer syndromes where
penetrance varies for cancer type and even cancer subtype. Further,
absence from control datasets has been proposed as moderate
evidence for variant pathogenicity (ACMG/AMP rule code PM2).
The most commonly used “control” reference sets (ExAC, and
more recently gnomAD) include males and females that were
ascertained for noncancer related studies mostly at ages younger
than the average age at onset of BRCA1/2‐related breast or ovarian
cancer, but individual‐level information about cancer phenotypes is
not available. Even assuming that these reference sets are largely
cancer unaffected, it must be considered that penetrance in female
pathogenic variant carriers for breast cancer is not complete, and
much lower for male carriers. Indeed, known pathogenic BRCA1/2
variants have been identified in these population control sets, even
after accounting for “founder” pathogenic variants (Maxwell, Dom-
chek, Nathanson, & Robson, 2016). As a result, the current ENIGMA
BRCA1/2 classification guidelines used empirical data to select
frequency cut‐offs for qualitative classification criteria (https://
enigmaconsortium.org/). Specifically, allele frequency ≥ 0.001 and <
0.01 in large outbred control reference groups was selected as a
component of evidence against pathogenicity, based on the upper
95% confidence interval (binomial Exact) of the frequency observed
for the most common pathogenic allele in non‐Finnish European and
other population groups drawn from ExAC and gnomAD. The
absence from controls has not yet been incorporated into the
ENIGMA BRCA1/2 guidelines.
To determine the utility of variant frequency in (or absence from)
reference population sets for future BRCA1 and BRCA2 variant
classification, and to formally assess the strength of this evidence, we
estimated a LR based on MAF in gnomAD v2.1 (noncancer), and
considered them against LR cut‐offs suggested for ACMG/AMP rules
(Tavtigian et al., 2018). Results are shown in Table 4. We considered
variants observed only once across all sample sets reviewed as a
separate category (see Methods), and categorized the remaining
variants into three MAF bins: 0.01 >MAF ≥ 0.0001; 0 <MAF <
0.0001; and not observed. The proportion of variants seen only
once across all five sample sets was 13.32% for (Likely) Benign
variants compared with 8.99% for (Likely) Pathogenic Variants, which
equates to an LR of 0.67, considered uninformative for pathogenicity
prediction. Variants classified as (Likely) Benign were spread
relatively evenly across the frequency categories, whereas (Likely)
Pathogenic variants were only seen at MAF < 0.0001, and the vast
majority (88%) were not seen in population controls. Assuming
conservatively a single (Likely) Pathogenic variant to fall in the
category “ ≥ 0.0001 & < 0.01,” the LR estimate is 0.05, equating to an
LR of 22.10 (3.12–156.21) against pathogenicity, considered strong
evidence that a variant is benign. The estimated LR against
pathogenicity for a variant seen in gnomAD at MAF < 0.0001 is
7.97 (2.59–24.50), which meets moderate evidence against patho-
genicity. Last, the estimated LR towards pathogenicity for a variant
not detected in gnomAD is 2.50 (2.16–2.91), corresponding to
supporting evidence in favor of pathogenicity; these findings suggest
that whereas “absence in controls” may be useful for BRCA1/2
variant classification, such evidence should carry less weight than the
PM2 moderate code proposed by ACMG/AMP for generic use.
Overall, these findings, based on empirical data, have utility to
inform the ongoing adjustment of the ENIGMA BRCA1/2 guidelines.
Use of these frequency cut‐offs for variants designated in this study
(Table S1) as Class 3 Uncertain or with posterior probability not
calculated, suggests strong evidence against pathogenicity for 98
variants, moderate evidence against pathogenicity for 147 variants,
and supporting evidence in favor of pathogenicity for 468 variants. It
is relevant to acknowledge that some variants detected in public
databases ‐ and also in clinical datasets ‐ may be somatic rather than
germline in origin, arising due to clonal hematopoiesis of indetermi-
nate potential. However, the proportion of variants arising due to
this mechanism is expected to be rare for BRCA1 and BRCA2
(estimated as < 0.2% of all pathogenic variants in one study of
>200,000 cancer gene tests (Coffee et al., 2017)), and we would also
TABLE 4 Frequency in reference population control sets for variants classified as (Likely) Benign or (Likely) Pathogenic using multifactorial
likelihood analysisa
(Likely) benign (Likely) pathogenic LR towards (95% confidence
Frequency category n % n % pathogenicity interval)
Single observation 59 13.32 8 8.99 0.67 (0.33–1.36)
≥ 0.0001 & < 0.01 110 24.83 0 1.12b 0.05 (0.01–0.32)
> 0 & < 0.0001 119 26.86 3 3.37 0.13 (0.04–0.39)
Not observed 155 34.99 78 87.64 2.50 (2.16–2.91)
Total 443 89
aSee methods for details of control datasets and assignment of frequency category.
bPercentage is calculated assuming a single variant in this category, and thus provides a conservative estimate of the LR.
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anticipate that the majority of such variants would be filtered out by
generic allele fraction cut‐offs used by sequencing pipelines set up to
detect true germline variants.
3.4 | Caveats, considerations, and conclusions
This study is the largest presentation of multifactorial likelihood
analysis to date. Although we mined existing public data and
requested clinical data for calculations from more than 300
individuals on the ENIGMA mailing list, we recognize that the
classifications assigned may alter with addition of data from other
sources, and/or with the application of qualitative classification
criteria. Efforts to collate information in a transparent manner that
retains patient confidentiality, and within the bounds of ethical
constraints, remain a challenge. As one step towards transparency,
we present summary estimates of LRs for the individual components
included in the analysis, and the sources of the different information
types. Further discussion, and probably technical developments, will
be required to determine how more detailed information, for
example, segregation scores for individual families, may be presented
for future large‐scale studies.
A prepublication iteration of the classification dataset was used
as a reference set for the Critical Assessment of Genome
Interpretation (CAGI) 5 experiment, results from which are pre-
sented in this same Journal issue (Cline et al., ). Comparison of various
different prediction methods from six different teams highlighted
that prediction of mRNA splicing is an important inclusion in variant
interpretation algorithms, and also indicated that variant interpreta-
tion may be improved by incorporating amino acid accessibility as a
component of bioinformatic prediction of variant effect. It also
showed that use of clinical information, when available, provides
significant improvements to variant classification over purely
bioinformatic approaches. In addition to the CAGI 5 experiment,
we chose to use an updated dataset for calibration of isolated data
types commonly used as components of qualitative classification
approaches. Specifically, the variant classifications from multifactor-
ial likelihood analysis were derived without use of laboratory splicing
and functional data, or variant frequency in outbred reference
populations. This allowed us to estimate independent LRs for or
against pathogenicity for these evidence types, with several
purposes: to assess the validity of ACMG/AMP code strengths
proposed for these evidence types when applying them to classifica-
tion of BRCA1/2 variants; to justify specific ENIGMA BRCA1/2
classification criteria incorporating population frequency or mRNA
splicing data; to provide guidance on incorporation of BRCA1/2
protein functional assay data, to assess BRCA1/2 predicted missense
variants specifically, in quantitative or qualitative (rules‐based)
classification models. We acknowledge that further analyses are
necessary before such LR estimations be formally reviewed and
incorporated into guidelines for BRCA1/2 Expert Panel variant
interpretations. Namely, it will be important to investigate LR
estimations with additional variants that have been previously
assessed using the multifactorial likelihood approach, and to derive
LRs separately for BRCA1 and BRCA2 given differences in the
penetrance for truncating variants in these two genes and the
potential for differences in sensitivity and specificity of different
laboratory assays to detect impact on function. Nevertheless, we
note that, despite the fact that known BRCA1/2 pathogenic variants
are seen in reference population datasets, and acknowledging
reservations that absence in control populations overall is not a
predictor of variant pathogenicity, it appears that this feature does
have value for examining the clinical relevance of rarer variants
presenting for assessment at this point in time; that is, accounting for
the fact that “known pathogenic” variants observed in control
datasets are more likely to have already been observed in the
clinical setting and already classified using other information types.
This observation highlights issues around constancy of evidence
strengths over time, and indicates that it will be important to
reconsider such analysis periodically to re‐estimate LRs and
corresponding rule strengths as the pool of variants remaining to
be classified alters over time. Following this line of thought, it will be
important that estimates of prior probability based on bioinformatic
predictions are re‐estimated using updated datasets that reflect
changed variant pools, and altered patient ascertainment in the era
of multigene panel testing. Results arising from the CAGI 5
experiment (Cline et al., ), and other similar studies, are likely to
inform development of such bioinformatic methods.
In summary, we have used the multifactorial likelihood analysis
approach to generate 248 new or considerably altered BRCA1/2
variant classifications, information that is relevant for medical manage-
ment – including determining patient eligibility for screening or PARPi
treatment, and cascade testing of their relatives. We have also shown
the value of this dataset for confirming existing ClinVar assertions, and
for calibration of additional data types useful for variant interpretation.
We have provided as supplementary information details regarding data
sources and likelihood scores for all variants investigated, so providing
a resource that will facilitate continued assessment of variants as
additional information accrues, and further calibration of new lines of
evidence relevant for variant interpretation.
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